Nagabushana Divya, Huynh Huan, McCauley Mark D, Serafini Anna
Epilepsy Division, Department of Neurology and Rehabilitation, University of Illinois Chicago, Chicago, Illinois, USA.
Department of Cardiology, University of Illinois Chicago, Chicago, Illinois, USA.
Epilepsia Open. 2025 Aug;10(4):1230-1235. doi: 10.1002/epi4.70061. Epub 2025 May 29.
Vagal nerve stimulation (VNS) is a form of neuromodulation that is an established adjunct in the management of drug-resistant epilepsy. The common side effects of VNS are cough, dysphonia, or shortness of breath, which are often mild and do not require discontinuation of therapy. However, serious adverse effects such as bradyarrhythmia and asystole can occur rarely in patients who have had VNS implanted several years ago due to certain technical issues, patient-related risk factors, and unknown causes that necessitate the deactivation of VNS. We describe the late onset of bradyarrhythmia in a 32-year-old patient with drug-resistant epilepsy 2 years after the implantation of VNS and the subsequent management. We also review similar cases in the literature to understand their mechanism of asystole and the antecedent risk factors. In conclusion, when selecting a patient for VNS, all the possible risk factors for adverse cardiac events should be considered. Initial EKG Holter prior to implantation and periodic monitoring is recommended for patients on VNS. PLAIN LANGUAGE SUMMARY: Vagal nerve stimulation (VNS) is a treatment used alongside medication for people with epilepsy who do not respond to drugs. It usually causes mild side effects such as cough or voice changes. Rarely, it can lead to serious heart problems such as slow heartbeat or heart stoppage, even years after the device is implanted. This report describes such a case in a 32-year-old patient and reviews similar cases to understand the risks. The authors recommend checking heart health with tests like an electrocardiogram before starting VNS and doing regular follow-up checks to help prevent serious complications.
迷走神经刺激术(VNS)是一种神经调节方式,是治疗耐药性癫痫的既定辅助手段。VNS的常见副作用包括咳嗽、声音嘶哑或呼吸急促,这些症状通常较轻,无需中断治疗。然而,由于某些技术问题、患者相关风险因素以及不明原因,在几年前植入VNS的患者中,可能会罕见地出现严重不良反应,如缓慢性心律失常和心搏停止,这就需要停用VNS。我们描述了一名32岁耐药性癫痫患者在植入VNS两年后出现迟发性缓慢性心律失常及后续处理情况。我们还回顾了文献中的类似病例,以了解心搏停止的机制及先前的风险因素。总之,在选择VNS治疗的患者时,应考虑所有可能的心脏不良事件风险因素。建议在植入前对患者进行初始心电图动态监测,并在VNS治疗期间进行定期监测。
迷走神经刺激术(VNS)是一种与药物联合使用的治疗方法,用于治疗对药物无反应的癫痫患者。它通常会引起咳嗽或声音变化等轻微副作用。很少情况下,即使在植入设备数年之后,它也可能导致严重的心脏问题,如心跳缓慢或心脏骤停。本报告描述了一名32岁患者的此类病例,并回顾了类似病例以了解风险。作者建议在开始VNS治疗前通过心电图等检查来检查心脏健康状况,并定期进行随访检查,以帮助预防严重并发症。